Combination therapy lowers blood pressure in patients receiving ibrutinib, reveals study Dr. Kamal Kant Kohli24 April 2024 9:30 PM ISTCombination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new...
Study Unveils Complexities of BP Management with Bruton's Tyrosine Kinase Inhibitors in Lymphoid Malignancies Dr.Niharika Harsha B24 Feb 2024 2:00 AM ISTIn a groundbreaking study, researchers have delved into the optimal approaches for managing hypertension (HTN) in patients undergoing Bruton's...
AbbVie plan to withdraw accelerated nods of Imbruvica in US for patients with certain types of blood cancer Ruchika Sharma7 April 2023 3:30 PM ISTIMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
Ibrutinib increases perioperative bleeding risk in patients with hematologic malignancies: Study Jacinthlyn Sylvia7 Oct 2022 7:30 PM ISTMinnesota: A new study published in the journal of Dermatologic Surgery suggests that patients with hematologic malignancies who use ibrutinib may...
Janssen bags USFDA nod for IMBRUVICA for chronic graft-versus-host disease treatment Ruchika Sharma28 Aug 2022 12:45 PM ISTChronic graft-versus-host disease is a life-threatening complication that can occur after a stem cell or bone marrow transplant when newly...
Ibrutinib with Chemoimmunotherapy Improved Progression-Free Survival of Newly Diagnosed Mantle Cell Lymphoma Patients Dr. Kamal Kant Kohli10 Jun 2022 7:15 PM ISTCombination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over...
Phase 3 SHINE results show postive results for IMBRUVICA (ibrutinib) in Mantle Cell Lymphoma Ruchika Sharma5 Jun 2022 3:00 PM ISTMCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.
Ibrutinib improves survival for younger people with diffuse large B-cell lymphoma Hina Zahid12 Jan 2022 9:00 AM ISTNew evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long some younger...
Ibrutinib, chemoimmunotherapy combination helps young CLL patients Dr. Nandita Mohan22 Dec 2021 2:59 PM ISTYoung patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the...
Medical Bulletin 21/December/2021 Dr. Nandita Mohan21 Dec 2021 5:13 PM ISTHere are Top Medical stories of the dayCalcitriol, Sirolimus combo helps treat ITPOverall efficacy of calcitriol combined with sirolimus in the...
Drug combination may keep young patients with chronic lymphocytic leukemia in remission for several years Hina Zahid18 Dec 2021 9:00 AM ISTYoung patients with chronic lymphocytic leukemia (CLL) can enjoy long remissions on the drug ibrutinib, but must stay on it indefinitely to keep the...
Natco Pharma loses patent litigation case over anti-cancer drug Ibrutinib in US Medical Dialogues Team25 Aug 2021 6:12 PM ISTNew Delhi: In a major setback, Natco Pharma has lost a legal battle with Pharmacyclics, a subsidiary of AbbVie over patent of anti-cancer drug...
